背景多形性胶质母细胞瘤(GBM)是一种恶性和侵袭性原发性脑肿瘤,预后不良。这种不良预后是由于持续的GBM细胞的高度侵入性导致的肿瘤进展和复发的趋势,这些细胞积极地从主要肿瘤块逃逸到周围的正常脑组织中。在生物标志物图解的基础上,它可以分为分子亚组。目的(1)确定IDH1、ATRX、免疫组织化学p53和Ki67,(2)为了确定GBM中任何这些生长控制基因的改变的蛋白质表达是否将显示与患者存活的关联。(3)建立具有预后特征的GBM分子亚群,无论组织病理学诊断。结果在这项前瞻性观察研究中,纳入了35例经组织学诊断的胶质母细胞瘤病例。演示时的平均年龄为43.46±17.25岁,男女比例为1.3:1。在35个案例中,23例可见微血管增生。10例可见较大的坏死灶(>50%),27例有丝分裂计数≥5/高倍视野(HPF)。在35个案例中,IDH1免疫阳性5例(14.3%),阴性30例(85.7%)。ATRX保留24例(68.6%),而在11例(31.4%)中丢失。31例(88.6%)p53免疫表达,4例(11.4%)p53阴性。总中位生存期(OS)为6个月。在两个蛋白质对中,三种成分为IDH1-/p53+(74.3%),ATRX+/IDH1-(62.9%),ATRX+/p53+(57.1%)。联合三蛋白免疫组织化学分析揭示了五种不同的分子变体。此外,8.6%(3/35)的样本存在三种蛋白的异常蛋白表达,即,ATRX-/p53+/IDH1+,11.4%(4/35)为野生型蛋白表达组,即,ATRX+/p53-/IDH1-。结论在单一蛋白表达的患者中,Kaplan-Meier生存分析显示IDH1突变胶质母细胞瘤的OS在统计学上更好。在双蛋白质对的情况下,IDH1/p53显示与更好的中位OS具有统计学意义。具有IDH1/ATRX/p53蛋白组合的患者的生存分析也表示更好的OS。因此,GBM可以单独使用这些蛋白质表达特征分为预后相关的亚组。以及组合的蛋白质表达特征。
Context Glioblastoma multiforme (GBM) is a malignant and aggressive primary brain tumor with a poor prognosis. This adverse prognosis is due to the tumor\'s tendency for advancement and recurrence caused by highly intrusive nature of the persisting GBM cells that actively escape from the main tumor mass into the surrounding normal brain tissue. On the basis of biomarker illustration, it can be classified into molecular subgroups. Aims (1) To determine the expression of
IDH1, ATRX, p53, and Ki67 by immunohistochemistry, in a cohort of GBMs. (2) To determine whether altered protein expression of any of these growth-control genes in GBM will show association with patient survival. (3) To establish prognostically distinct molecular subgroups of GBM, irrespective of histopathological diagnosis. Results In this prospective observational study, 35 histologically diagnosed cases of glioblastoma were enrolled. The mean age at the time of presentation was 43.46 ± 17.25 years with a male:female ratio of 1.3:1. Of the 35 cases, microvascular proliferation was seen in 23 cases. Large foci of necrosis (>50%) were seen in 10 cases and 27 cases had mitotic count ≥ 5/high power field (HPF). Of 35 cases, 5 (14.3%) cases showed
IDH1 immunopositivity and 30 (85.7%) cases were negative for
IDH1. ATRX was retained in 24 (68.6%) cases, while it was lost in 11 (31.4%) cases. The p53 immunoexpression was seen in 31 (88.6%) cases, whereas p53 was negative in 4 (11.4%) cases. The overall median survival (OS) was 6 months. In two protein pairs, the three compositions were
IDH1-/p53+ (74.3%), ATRX +/
IDH1- (62.9%), and ATRX +/p53+ (57.1%). Combined three-protein immunohistochemical analysis revealed five different molecular variants. Also, 8.6% (3/35) of the samples had aberrant protein expression of all three proteins, i.e., ATRX-/p53 +/IDH1 + , while 11.4% (4/35) were wild-type protein expression group, i.e., ATRX +/p53-/
IDH1-. Conclusion In patients with single protein expression, Kaplan-Meier survival analysis showed statistically better OS in IDH1 mutant glioblastomas. In cases with double protein pairs, IDH1/p53 revealed statistically significant association with better median OS. The survival analysis of patients with
IDH1/ATRX/p53 protein combinations also denoted a better OS. Hence, GBM can be grouped into prognostically relevant subgroups using these protein expression signatures individually, as well as the combined protein expression signatures.